Press Releases

Panbela Announces Publication of Preclinical Data Titled: Expanded Potential of the Polyamine Analogue SBP-101 (Diethyl Dihydroxyhomospermine) as a Modulator of Polyamine Metabolism and Cancer Therapeutic

In vitro studies determined that SBP-101 reduced cellular viability across a broad range of cancer cell types, with an exceptionally strong reduction in ovarian adenocarcinoma viability resulting in a 42% increase in median survival in VDID8+ ovarian cancer mouse model.

Panbela Therapeutics, Inc. Closes Acquisition of Cancer Prevention Pharmaceuticals, Inc.

Panbela Provides Business Update and Reports Q1 2022 Financial Results

Panbela to Host Virtual R&D Day

Panbela Schedules Conference Call on May 12 to Report 2022 Q1 Financial Results

Panbela Announces Poster Presentation at American Association for Cancer Research: The potential of spermine analogue SBP-101 (diethyl dihydroxyhomospermine) as a polyamine metabolism modulator in ovarian cancer

Panbela Provides Business Update and Reports Q4 and FY 2021 Financial Results

Panbela to Participate in a Panel Discussion: “Pancreatic Cancer- Turning the Tide for One of the Most Challenging Indications in Oncology,” at the Maxim Virtual Growth Conference on March 28 at 12pm ET

Panbela to Participate in the 34th Annual Roth Conference

• Panbela management will participate in a fireside chat at the 34th Annual Roth Conference on March 14, 2022, at 11:30AM PT.
• The webcast will be available at: https://wsw.com/webcast/roth43/pbla/1805948

Panbela Schedules Conference Call on 3/24/22 to Report 2021 Fourth Quarter Financial Results